Fathom Therapeutics Appoints Bret Williams as Chief Scientific Officer to Advance Microcosmos Platform

On October 29, 2026, Fathom Therapeutics announced the appointment of Bret Williams, Ph.D., as its new Chief Scientific Officer (CSO). Dr. Williams is tasked with leading the translation of molecular insights generated by the company’s proprietary Microcosmos platform into a formalized portfolio of therapeutic programs. This development follows a $55 million Series A financing round secured in May 2026.

Strategic Role and Background

In his new capacity, Dr. Williams will oversee the transition of novel drug candidates from initial design to clinical development. His background includes over 20 years of experience in drug discovery, with specific expertise in artificial intelligence (AI) and machine learning (ML) applications within oncology, autoimmune, and rare diseases.

• Prior Experience: Most recently served as Senior Vice President and Head of Research at Magnet Biomedicine.
• Leadership History: Held significant roles at Relay Therapeutics and Sanofi, focusing on target identification and molecular discovery.
• Academic Credentials: Completed his postdoctoral fellowship at MIT and holds a Ph.D. in cellular and molecular biology from the University of Wisconsin-Madison.

Technology and Future Pipeline

Fathom Therapeutics utilizes physics-based simulations and AI to model protein dynamics at atomic resolution. By predicting how proteins behave within living cells, the company aims to design small molecule medicines for targets that have historically been considered "undruggable." According to the company, the Microcosmos platform provides data necessary to improve therapeutic selectivity and reduce potential off-target risks.

"Fathom Therapeutics was founded by the pioneers in simulating protein-drug interactions," noted Dr. Williams, highlighting the company’s focus on the precision of its simulations. The firm currently maintains headquarters in New York with an additional presence in Boston. Interested parties may verify corporate announcements through the company's official website or official press release channels.